---
figid: PMC3916982__BR-02-01-0041-g01
figtitle: Crosstalk of signaling pathways in breast cancer and the potential clinical
  therapeutic targets
organisms:
- NA
pmcid: PMC3916982
filename: BR-02-01-0041-g01.jpg
figlink: /pmc/articles/PMC3916982/figure/f2-br-02-01-0041/
number: F2
caption: 'Crosstalk of signaling pathways in breast cancer and the potential clinical
  therapeutic targets. The receptors of extracellular small molecules shown here include:
  epidermal growth factor (EGF), transforming growth factor (TGF)-β, vascular endothelial
  growth factor (VEGF), fibroblast growth factor (FGF), insulin-like growth factor
  (IGF)-1, insulin and estrogen, which activate their corresponding receptors and
  further transduce the signals mainly through the phosphatidylinositol-3-kinase (PI3K)/AKT
  pathway or the Ras/MEK pathway. A number of PI3K/AKT and Ras/MEK signaling pathway
  inhibitors have been developed, some of which may be used in combination (details
  also summarized in ). Pg, progesterone; ER, estrogen receptor; PR, progesterone
  receptor; ERK, extracellular signal-regulated kinase; RSK, ribosomal S6 kinase;
  IP, inositol phosphate; PKC, protein kinase C; PTEN, phosphatase and tensin homolog;
  PDK, phosphoinositide-dependent kinase; mTOR, mammalian target of rapamycin; MAPK,
  mitogen-activated protein kinase.'
papertitle: Estrogen receptor-positive breast cancer molecular signatures and therapeutic
  potentials (Review).
reftext: MEI HONG ZHANG, et al. Biomed Rep. 2014 Jan;2(1):41-52.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8367824
figid_alias: PMC3916982__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC3916982__F2
ndex: 9703334a-df23-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3916982__BR-02-01-0041-g01.html
  '@type': Dataset
  description: 'Crosstalk of signaling pathways in breast cancer and the potential
    clinical therapeutic targets. The receptors of extracellular small molecules shown
    here include: epidermal growth factor (EGF), transforming growth factor (TGF)-β,
    vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), insulin-like
    growth factor (IGF)-1, insulin and estrogen, which activate their corresponding
    receptors and further transduce the signals mainly through the phosphatidylinositol-3-kinase
    (PI3K)/AKT pathway or the Ras/MEK pathway. A number of PI3K/AKT and Ras/MEK signaling
    pathway inhibitors have been developed, some of which may be used in combination
    (details also summarized in ). Pg, progesterone; ER, estrogen receptor; PR, progesterone
    receptor; ERK, extracellular signal-regulated kinase; RSK, ribosomal S6 kinase;
    IP, inositol phosphate; PKC, protein kinase C; PTEN, phosphatase and tensin homolog;
    PDK, phosphoinositide-dependent kinase; mTOR, mammalian target of rapamycin; MAPK,
    mitogen-activated protein kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - btl
  - htl
  - Egfr
  - pe
  - pr
  - es
  - Sos
  - Shc
  - norpA
  - sl
  - Plc21C
  - ras
  - Ras64B
  - Ras85D
  - ctp
  - Nf1
  - Raf
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Pten
  - Myb
  - Pi3K21B
  - Taf5
  - Dsor1
  - Mtk
  - MKP-4
  - p38b
  - rl
  - Akt
  - Rheb
  - Erk7
  - Tsc
  - Tsc1
  - gig
  - IKKepsilon
  - key
  - IKKbeta
  - S6k
  - cass
  - S6kII
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - Debcl
  - eIF4E1
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E6
  - eIF4EHP
  - CycD
  - p53
  - betaTub60D
  - hth
  - CycE
  - cyc
  - DNMT3B
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - EGFR
  - ERBB2
  - IGF1R
  - XYLT2
  - SOS1
  - SOS2
  - CNR2
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - C2
  - FRS2
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - KRAS
  - HRAS
  - NRAS
  - SLC25A1
  - NF1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - CUX1
  - NPPA
  - PTEN
  - MTG1
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - SERPINB10
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - RHEB
  - RHEBP1
  - EPHB2
  - SLC12A3
  - TSC1
  - TESC
  - TSC2
  - MDM2
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - RPS6KB1
  - BAD
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - RPS6KB2
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - BCL2L1
  - BCL2
  - EIF4E
  - EIF4E2
  - EIF4E3
  - CCND1
  - CCND2
  - CCND3
  - TP53
  - TP63
  - TP73
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
